A Novel GBF1 Variant in a Charcot-Marie-Tooth Type 2: Insights from Familial Analysis
Genes · 2024
DOI: 10.3390/genes15121556 ↗Kurz gefasst
Fallbericht in der Zeitschrift Genes, 2024. Verfasst von Valentina Ciampana und 6 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Unit, Department of Translational Medicine, Maggiore Della Carità Hospital, University of Piemonte Orientale, 28100 Novara, Italy. Hauptthemen laut MEDLINE: Charcot-Marie-Tooth Disease, Guanine Nucleotide Exchange Factors, Pedigree. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Axonal Charcot–Marie–Tooth disease type 2 (CMT2) accounts for 24% of Hereditary Motor/Sensory Peripheral Neuropathies. CMT2 type GG, due to four distinct heterozygous mutations in the Golgi brefeldin A resistant guanine nucleotide exchange factor 1 (GBF1) gene (OMIM 606483), was described in seven cases from four unrelated families with autosomal dominant inheritance. It is characterized by slowly progressive distal muscle weakness and atrophy, primarily affecting the lower limbs. Here, we present two siblings sharing a novel GBF1 variant.
Methods
Patient II.1 (male, 61 years at onset) presented lower limb hypoesthesia and walking difficulty; the examination revealed a postural tremor, a positive Romberg test, and muscle atrophy in the lower limbs and hands. Patient II.2 (his sister, 59 years at onset) had lower limb dysesthesias, hand paresthesia, and lower-limb stiffness. They underwent clinical evaluations, blood tests, and electroneurography. Their father represents a potentially affected individual, although a genetic analysis was not conducted.
Results
All tests for peripheral neuropathies were unremarkable, including metabolic and autoimmune screening. Both showed a mixed demyelinating–axonal sensory–motor neuropathy. Genetic analysis revealed a new heterozygous GBF1 variant of uncertain significance.
Conclusions
Based on autosomal dominant inheritance, as well as clinical and physiological features, a possible novel CMT2GG was diagnosed. Further research, including functional assays and in vitro studies, is necessary to confirm this variant’s causal link.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurology Unit, Department of Translational Medicine, Maggiore Della Carità Hospital, University of Piemonte Orientale, 28100 Novara, Italy.
- Department of Translational Medicine, Genetic Laboratory, Università del Piemonte Orientale (UPO), 28100 Novara, Italy.
- Department of Health Sciences, Center on Autoimmune and Allergic Diseases (CAAD), University of Piemonte Orientale (UPO), 28100 Novara, Italy.
- Parkinson Institute of Milan, ASST G.Pini-CTO, 20122 Milano, Italy.
ORCID-Profile: Lucia Corrado, Luca Magistrelli, Elena Contaldi, Cristoforo Comi, Domizia Vecchio
Zitieren
APA
Ciampana, V., Corrado, L., Magistrelli, L., Contaldi, E., Comi, C., D'Alfonso, S., & Vecchio, D. (2024). A Novel GBF1 Variant in a Charcot-Marie-Tooth Type 2: Insights from Familial Analysis. Genes. https://doi.org/10.3390/genes15121556
Vancouver
Ciampana V, Corrado L, Magistrelli L, Contaldi E, Comi C, D'Alfonso S, et al. A Novel GBF1 Variant in a Charcot-Marie-Tooth Type 2: Insights from Familial Analysis. Genes. 2024. doi:10.3390/genes15121556
BibTeX
@article{Ciampana2024,
author = {Ciampana, Valentina and Corrado, Lucia and Magistrelli, Luca and Contaldi, Elena and Comi, Cristoforo and D'Alfonso, Sandra and Vecchio, Domizia},
title = {A Novel GBF1 Variant in a Charcot-Marie-Tooth Type 2: Insights from Familial Analysis},
journal = {Genes},
year = {2024},
doi = {10.3390/genes15121556}
}
EUVIMED